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Abstract
Purpose—The purpose of this study is to examine reporting of treatment summaries and follow-
up instructions among cancer survivors.
Methods—Using the 2010 National Health Interview Survey, we created logistic regression 
models among cancer survivors not in treatment (n= 1,345) to determine characteristics associated 
with reporting treatment summaries and written follow-up instructions, adjusting for 
Correspondence to: Susan A. Sabatino.
Conflict of interest The authors report no conflicts of interest.
Disclaimers The findings and conclusions in this report are those of the authors and do not necessarily represent the official position 
of the Centers for Disease Control and Prevention or the National Cancer Institute.
HHS Public Access
Author manuscript
J Cancer Surviv. Author manuscript; available in PMC 2018 March 14.
Published in final edited form as:
J Cancer Surviv. 2013 March ; 7(1): 32–43. doi:10.1007/s11764-012-0242-x.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
sociodemographic, access, and cancer-related factors. Findings are presented for all survivors and 
those recently diagnosed (≤4 years). We also examined unadjusted associations between written 
instructions and subsequent surveillance and screening.
Results—Among those recently diagnosed, 38 % reported receiving treatment summaries and 
58 % reported written instructions. Among all survivors, approximately one third reported 
summaries and 44 % reported written instructions. After adjustment, lower reporting of summaries 
was associated with cancer site, race, and number of treatment modalities among those recently 
diagnosed, and white vs. black or Hispanic race/ethnicity, breast vs. colorectal cancer, >10 vs. ≤5 
years since diagnosis, no clinical trials participation, and better than fair health among all 
survivors. For instructions, lower reporting was associated with no trials participation and lower 
income among those recently diagnosed, and increasing age, white vs. black race, lower income, 
>10 vs. ≤5 years since diagnosis, 1 vs. ≥2 treatment modalities, no trials participation, and at least 
good vs. fair/poor health among all survivors. Written instructions were associated with reporting 
provider recommendations for breast and cervical cancer surveillance, and recent screening 
mammograms.
Conclusion—Many recently diagnosed cancer survivors did not report receiving treatment 
summaries and written follow-up instructions. Opportunities exist to examine associations 
between use of these documents and recommended care and outcomes, and to facilitate their 
adoption.
Implications for cancer survivors—Cancer survivors who have completed therapy should 
ask their providers for treatment summaries and written follow-up instructions, and discuss with 
them how their cancer and therapy impact their future health care.
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Introduction
The cancer survivor population is large and growing with nearly 12 million U.S. adult cancer 
survivors [1, 2]. As survivors live longer, increasing attention has focused on long-term care. 
Survivors are at risk for recurrence, second primary cancers [3], and late and long-term 
effects of cancer and treatment [4]. Because health risks vary, individualized risk assessment 
and management is needed [5].
Health problems among survivors may not develop for years [6, 7]. Given concerns about 
the sustainability of the cancer specialist workforce providing long-term follow-up care [8, 
9], and that follow-up may be provided by primary care providers (PCPs) [10, 11], 
coordinated care is important [5, 12]. However, there may be suboptimal communication 
between PCPs and oncologists [13, 14], who may have discordant perceptions of their roles 
[15], leaving some PCPs with inadequate knowledge of survivors’ health history and risks 
[16], and many survivors unsure which provider is in charge of their follow-up care [17].
A recent Institute of Medicine (IOM) report noted that many survivors get lost to follow-up 
during the transition from active treatment to posttreatment care [12]. In response, 
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survivorship care plans have been developed to summarize cancer and treatment history, 
needed screening, surveillance and preventive care, and specify providers responsible for 
follow-up [5, 12, 18]. Treatment summaries and written follow-up instructions are 
recommended care plan components [12, 19]. Care plans are recommended or supported by 
many expert organizations [12, 19, 20], with delivery of treatment summaries, a key 
component of plans, endorsed by the American Society of Clinical Oncology (http://
qopi.asco.org/Documents/QOPISpring2011MeasuresSummary_000.pdf), the Physician 
Consortium for Performance Improvement (http://www.ama-assn.org/ama/pub/physician-
resources/clinical-practice-improvement/clinical-quality/physician-consortium-performance-
improvement/pcpi-measures.page), and the Commission on Cancer (http://www.facs.org/
cancer/coc/programstandards2012.html). However, little is known about how frequently 
plans are used among adult cancer survivors, and national estimates of care plan use are 
lacking.
National estimates would provide information about current care plan use and which 
survivors are least likely to receive plans. This information would be valuable to cancer 
clinicians, survivors, and decision makers in raising awareness about delivering care plans 
and survivors’ long-term care needs. This information would also be useful to researchers 
and others in evaluating the impact of plans on morbidity and mortality, developing 
interventions to promote care plan use, and identifying a national baseline for future 
monitoring. We examined the extent to which survivors of adult-onset cancers report having 
received treatment summaries and follow-up instructions, variations in receipt, and whether 
follow-up instructions are associated with subsequent care. We present findings for those 
diagnosed within 4 years, who were diagnosed after the release of reports in 2004–2005 
calling for delivery of these documents to survivors (http://www.nap.edu/catalog.php?
record_id=11468) [12, 19]. We also separately present findings for all survivors. Although 
many survivors in this group were diagnosed prior to release of these reports and therefore 
may not have been expected to have received these documents, findings among all survivors 
may identify groups who may benefit and/or whose providers may benefit from further 
education about their treatment history and future care needs.
Methods
We used data from the 2010 National Health Interview Survey (NHIS) [21], a nationally 
representative sample of the civilian, non-institutionalized U.S. population. NHIS is an 
annual survey administered by the Centers for Disease Control and Prevention’s National 
Center for Health Statistics (NCHS) through in-person interviews. The final sample adult 
response rate was 60.8 % [21].
Our sample included adult cancer survivors (n=2,333), except those whose most recent 
cancer was non-melanoma skin cancer, skin cancer of uncertain type, or unknown type 
(n=549); who were in active treatment (n=108); did not report treatment (n=98); and had 
unknown information about whether treatment was received (n=173) or active (n=14). 
Because our focus was on survivors of adult-onset cancers, we also excluded 46 respondents 
whose age at diagnosis was before age 18 or unknown.
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Primary dependent variables included self-reported receipt of a treatment summary and 
follow-up instruction as determined by: “At the completion of your cancer treatment(s), did 
your doctor give you a single written document describing ALL the treatments you actually 
received? This would NOT include general pamphlets about cancer treatments or individual 
lab results” and “Have you EVER received advice from a doctor, nurse, or other health care 
professional about where you should return or who you should see for routine cancer check-
ups after completing treatment for cancer? Not including appointment cards or reminders, 
was this information written down, printed on paper, or provided in an electronic format for 
you?” We categorized follow-up instructions as written/textual, unwritten or none. We 
categorized written and unwritten instructions separately because the IOM report indicates 
that such information should be provided to survivors in a written format [12]. Other 
dependent variables included use of recent surveillance to monitor for recurrence, other 
cancer screening, provider recommendations for surveillance and screening, and having a 
usual provider.
Surveillance and screening definitions were based on National Comprehensive Cancer 
Network guidelines (www.nccn.org) and U.S. Preventive Services Task Force 
recommendations (http://www.uspreventiveservicestaskforce.org/recommendations.htm), 
respectively (Table 1). To examine associations of instructions with subsequent cancer 
screening, we excluded screening tests prior to diagnosis and limited analyses to survivors 
≥1 year post-diagnosis. We did not report lung cancer surveillance or provider 
recommendations for colorectal cancer surveillance because of small cell sizes and/or large 
relative standard errors. For provider recommendations, NHIS respondents aged ≥40 with no 
recent colorectal cancer test were asked whether a healthcare provider recommended one 
within the prior year. Provider recommendation questions for Pap and mammography 
pertained to the prior year and were asked of respondents who did and did not report 
receiving recent tests.
Independent variables included age, sex, race/ethnicity, education, income measured as 
percentage of federal poverty thresholds (FPL), insurance, health status, clinical trial 
participation, and cancer site, age at diagnosis, time since diagnosis, number of treatment 
modalities received, and recency of treatment for the most recent cancer. Insurance was 
categorized as any private or military insurance (“private”), public insurance only, and no 
insurance or only single service plan coverage (n=3, all excluded cancer care). For time 
since diagnosis, we subtracted age at diagnosis from age at interview. Treatments included 
surgery, radiation, chemotherapy, hormonal treatments, bone marrow/stem cell transplants or 
other. Because NHIS inquired about receipt of summaries of all treatments received, we 
categorized treatment by number of modalities. Treatment recency included whether non-
hormonal treatments were received within 1 year.
To examine the proportion of survivors who report having received these documents among 
those diagnosed after recommendations for their use were issued, we present findings for 
those diagnosed within 4 years. To examine the proportion of all survivors who report not 
having received these documents and may benefit from additional information about their 
treatment history and future care needs, we separately present findings for all survivors. 
Pearson chi-square tests were used to test differences in weighted percentages. Multivariable 
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logistic regression models were created to determine characteristics independently 
associated with reporting treatment summaries and written follow-up instructions. The 
linearity assumption for continuous predictors (age and income) was assessed using 
restricted cubic spline functions [22]. Relationships with each outcome were linear. P values 
reflect simultaneously testing that all regression coefficients for a given variable equal zero.
NCHS imputes missing data for income using multiple imputation [21]. Missing data for 
time since diagnosis were multiply imputed (five imputations) using the aregImpute function 
from the Hmisc [23] package in R [24]. Of 74 survivors with incomplete time since 
diagnosis due to age truncation in NHIS or missing data, 52 had minimum times available. 
Partial timing information was used in imputation with imputed values defined as the 
maximum of observed minimum times since diagnosis and predicted times from the 
imputation. All independent variables, outcome variables, and sampling weights were 
included in the imputation. We weighted all statistics and used SUDAAN version 10.0.1 
(Research Triangle Institute, Research Triangle Park, NC) and SAS version 9.2 (SAS 
Institute Inc, Cary, NC) to account for the complex survey design.
Results
Of 1,345 survivors, 52 % were younger than 65 (range, 20–85+; Table 2). Most were female, 
white, privately insured, and had at least some college education. Breast cancer survivors 
predominated. Approximately 40 % reported diagnosis ≤5 or >10 years prior. Most survivors 
reported one treatment modality, no recent treatments, no clinical trials participation, and at 
least good health.
Among recently diagnosed survivors (within 4 years), 29.4 % reported receiving both 
treatment summaries and written follow-up instructions and 33.1 % reported neither. Among 
all survivors, 22 % reported receiving both documents, while 45 % reported neither. Among 
those recently diagnosed, 38 % reported summaries, and no factors in unadjusted analyses 
were significantly associated with recalling having received a treatment summary, although 
findings by cancer site were of borderline significance (p=.059; Table 3). Among all 
survivors, 32 % reported receiving treatment summaries. Survivors with age ≥80, white race, 
cancers other than prostate, colorectal or cervical, diagnosis >10 years prior, no trials 
participation, and better than fair health status were less likely to report summaries than 
survivors with age 50–64 years, black race or Hispanic ethnicity, prostate or colorectal 
cancer, diagnosis within 5 years, trials participation, and fair/poor health status, respectively.
Written follow-up instructions were reported by 58 % of recently diagnosed survivors (Table 
4). In this group, those who did not participate in clinical trials were less likely to report 
written instructions. Among all survivors, 44 % reported receiving written follow-up 
instructions. Survivors with age ≥80 years, white race, no college education, income <250 % 
FPL, no insurance, diagnosis >10 years prior, no recent treatment, and no trials participation 
were less likely to report written instructions than those with age <80, black race, at least 
some college, income ≥400 % FPL, private insurance, diagnosis within 10 years, recent 
treatment, and trial participation, respectively. Uterine cancer survivors were least likely to 
report written instructions (<20 vs. >50 % of prostate or colorectal cancer survivors). 
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Survivors reporting one treatment modality were more likely to report not having received 
any follow-up instructions. Among survivors with age ≥80, no insurance, uterine cancer, or 
diagnosis >10 years prior, 40–50 % reported no instructions at all.
After adjustment, race/ethnicity, cancer site, and number of treatment modalities were 
significantly associated with reporting having received treatment summaries among those 
recently diagnosed (Table 5). Black survivors were more likely than white survivors and 
colorectal cancer survivors were more likely than breast cancer survivors to report having 
received a summary. More than one treatment modality was associated with a lower 
likelihood of reporting a summary than one modality. Among all survivors, differences 
between colorectal and breast cancer survivors, and by race, time since diagnosis, clinical 
trial participation, and health status retained significance after adjustment.
For written instructions, after controlling for other factors, clinical trials participation was a 
strong predictor of reporting having received written instructions among recently diagnosed 
survivors. Income also achieved significance, with higher income survivors more likely to 
report written instructions. Among all survivors, lower reported receipt was associated with 
increasing age, white vs. black race, decreasing income, >10 vs. ≤5 years since diagnosis, 
one treatment modality, no clinical trials participation, and better than fair vs. fair/poor 
health.
Written instructions were associated with reporting recent provider recommendations for 
breast and cervical cancer surveillance, although not test use (Table 6). For prostate cancer, 
unwritten instructions were associated with greater PSA surveillance. For screening, written 
instructions were associated with recent mammography use.
Discussion
Major reports recommending that providers deliver treatment summaries and written follow-
up instructions to cancer survivors upon completion of treatment were released in 2004–
2005 (http://www.nap.edu/catalog.php?record_id=11468) [12, 19]. Our analysis of survivors 
diagnosed after that time suggests that reported receipt of these documents was low with 40–
60 % not reporting having received them. Not surprisingly, when examining all survivors, 
including those diagnosed before issuance of these reports, rates were even lower. Findings 
for the full sample are important however, not necessarily as a measure of quality of care, 
since most of this group was diagnosed prior to release of these reports, but rather as a 
baseline measure and an indication of the proportion of survivors who might benefit from 
additional information about their diagnosis, treatment history, and future care needs. More 
than one quarter of survivors did not recall any follow-up instructions, including 40–50 % of 
the oldest survivors, those uninsured, diagnosed >10 years prior, or surviving uterine cancer. 
This is important given many survivors are unsure who manages their follow-up [17], are 
insufficiently aware of their continuing health risks [25, 26], and may lack regular follow-up 
for possible late effects and recommended services [25, 27–29]. We are unaware of previous 
national estimates of these measures. Findings for these documents are consistent with 
reports and assertions that care plans and treatment summaries are not implemented widely 
[5, 30], and with gaps reported by survivors regarding treatment information received [30].
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Some survivors were less likely to report receiving these documents, including those with no 
clinical trials participation or diagnosed >10 years prior. This is not surprising given the 
recent emergence of care plans and attention to treatment summaries, and the increased 
documentation and healthcare system contact with clinical trials. However, findings indicate 
that these groups and providers delivering their long-term care may need further education 
about their treatment history and best course of follow-up. Greater reported receipt of 
treatment summaries by colorectal vs. breast cancer survivors both overall and among those 
recently diagnosed is somewhat surprising given the relatively early promotion of breast 
cancer care plan templates. Potential contributing factors might include differences in 
treatment modalities, facilities, or providers. Breast cancer survivors were more likely to 
report receiving radiation (44 vs. 19 %), hormonal treatments (26 vs. <1 %), and 
chemotherapy (39 vs. 33 %). Racial/ethnic differences in reporting treatment summaries also 
existed in both groups of survivors, even after adjusting for socioeconomic and cancer-
related factors. It is not clear why this is the case. Potential factors that may contribute in 
part to such differences could include differences in healthcare settings or systems [31, 32], 
comorbidity burden [32], or interpretation of or response to survey questions. Confirmation 
of these findings is needed. A lower likelihood of reporting treatment summaries among 
those with more than one treatment modality could reflect more difficulty compiling 
treatment history for those who received different forms of treatment from multiple 
providers.
For follow-up instructions, we examined written instructions separately because the IOM 
report states instructions should be in writing [12]. Among recently diagnosed survivors, 
increasing income was associated with likelihood of reporting having received written 
instructions, and clinical trials participation was a strong predictor of reporting written 
instructions. Although reporting written instructions was greater among survivors diagnosed 
<4 vs. >4 years for both trials, participants and non-participants, differences by participation 
were greater for recently diagnosed survivors (not shown). Among all survivors, age, race, 
time since diagnosis, number of treatment modalities, and health status were associated with 
reporting of written instructions in addition to income and trials participation. Decreased life 
expectancy among older survivors may prompt discontinuation of surveillance and 
screening, leading to less detailed follow-up planning. However, some older survivors were 
likely diagnosed at younger ages when life expectancy was longer. Greater recall for those in 
fair/poor health may reflect increased healthcare system contact.
Studies examining the impact of these documents are few given the nascency of research in 
this area [8, 33]. The IOM concluded that care plans “have strong face validity and can 
reasonably be assumed to improve care unless and until evidence accumulates to the 
contrary” [12]. Among childhood Hodgkin’s lymphoma survivors, care plans may lead to 
completion of recommended surveillance [34]. We found that written follow-up instructions 
may be more highly associated with some recommended surveillance than screening, most 
notably provider surveillance recommendations. Except for prostate cancer surveillance, 
compared with no instructions significant increases in recommending or completing 
surveillance or screening were driven by written rather than unwritten instructions. However, 
findings for surveillance and screening were based on small numbers and unadjusted, so 
confirmation is needed.
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Study limitations include that NHIS data are self-reported and do not necessarily reflect 
actual document delivery. Inquiring about treatment summaries and follow-up instruction 
may not reflect use of comprehensive survivorship care plans. Recall may be an issue, 
particularly for survivors farther from diagnosis, and interpretation of findings for those 
diagnosed more than 4 years prior should consider that recommendations for use of these 
documents were not in place at that time. However, findings may indicate survivors and their 
providers who may benefit from additional information about their history and future 
recommended care. NHIS does not provide information about stage at diagnosis. Thus, it is 
possible that patients with metastatic disease could be in our sample. However, in order to 
focus our analysis on survivors not undergoing cancer treatment, we excluded survivors 
actively receiving treatment for whom treatment summaries and follow-up instructions may 
have been inappropriate. Furthermore, approximately 90 % of survivors reported being > 1 
year beyond completion of treatment. These factors likely reduce the chance that such 
patients were included. Our sample also may not reflect all cancer survivors. Compared with 
U.S. prevalence data [2], a smaller proportion of our sample was older than 65 (60 vs. 
47 %), male (46 vs. 41 %), or had prostate cancer (19 vs. 14 %), and more reported cervical 
cancer (2 vs. 9%) or melanoma (7 vs. 11%). Overreporting cervical cancer and 
underreporting other cancers, including prostate, in national surveys have been documented 
[35]. Younger age in our sample may have contributed to the lower proportion of prostate 
cancer survivors. NHIS data also are limited to noninstitutionalized individuals; therefore, 
findings for institutionalized survivors are not incorporated, nor are those for survivors who 
died after treatment or were too ill to participate. Finally, some variables such as insurance 
are as of time of interview and not diagnosis.
Among recently diagnosed cancer survivors, many did not report receiving treatment 
summaries and written follow-up instructions, key components of survivorship care plans, 
with repotted receipt even lower for some groups. Although care plans may not be 
appropriate for all cancer survivors, this would likely not explain why so many recently 
diagnosed survivors did not report receiving these documents. Findings suggest that 
implementation of these documents is in a relatively early stage of adoption, and that 
opportunities exist to educate providers and survivors about their recommended use to help 
them understand care received, and identify current and future needs. For researchers and 
others, findings indicate a need to examine further the impact of these documents on 
recommended health services use and outcomes, identify key barriers [5, 8] to. their 
delivery, develop effective interventions to facilitate their use, and monitor progress from the 
baseline established by these findings.
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Table 1
Cancer surveillance and screening definitions
Surveillancea,b
 Breast cancer survivors Mammogram within 1 year
 Colorectal cancer survivorsc Colonoscopy within 5 years
 Cervical cancer survivors Pap within 1 year
 Prostate cancer survivors PSA within 1 year
 Lung cancer survivors Chest CT within 1 year
Screeningd
 Mammogram Mammogram within 2 years among female survivors aged 50–74 without breast cancer
 Colorectal cancer FOBT within 1 year, flexible sigmoidoscopy within 5 years, and FOBT within 3 years, or colonoscopy within 
10 years among survivors aged 50–75 without colorectal cancer
 Pap test Pap test within 3 years among female survivors aged 21–65 without cervical cancer or hysterectomy
PSA prostate-specific antigen, FOBT fecal occult blood test
a
Monitors for disease recurrence
bAmong survivors not treated within 1 year
c
Because guidelines for survivors <5 years post-diagnosis are conditional on timing and findings of previous tests, we limited analysis to ≥5 years 
post-diagnosis
d
Monitors for new cancers. Limited to survivors >1 year post-diagnosis
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Table 2
Characteristics of survivors of adult-onset cancers not in active treatment, NHIS 2010
All survivors, N= 1,345
N (%)
Diagnosis ≤4 yearsb, N=407
N (%)
Age
 <50 258 (20.0) 100 (24.5)
 50–64 409 (32.1) 141 (36.3)
 65–79 450 (33.9) 142 (34.4)
 ≥80 228 (14.0) 24 (4.7)
Sex
 Male 494 (40.9) 180 (48.4)
 Female 851 (59.1) 227 (51.6)
Race/ethnicity
 Hispanic 123 (5.7) 46 (6.8)
 Non-Hispanic White 989 (83.1) 290 (81.2)
 Non-Hispanic Black 180 (8.4) 56 (8.8)
 Non-Hispanic Other 53 (2.9) 15 (3.1)
Education
 ≤High school 575 (41.2) 163 (37.6)
 ≥Some college 766 (58.8) 241 (62.4)
Income (% FPL)
 <250 % 608 (37.9) 172 (34.6)
 250–<400 % 295 (23.8) 92 (25.8)
 ≥400 % 441 (38.2) 142 (39.6)
Insurance
 Any private/military 882 (69.1) 270 (69.8)
 Public only 378 (24.8) 110 (23.9)
 Single service/none 85 (6.1) 27 (6.3)
Diagnosisa
 Breast 307 (20.4) 81 (19.1)
 Prostate 188 (14.4) 73 (19.5)
 Cervix 123 (8.7) 20 (3.7)
 Melanoma 125 (11.0) 36 (10.1)
 Colorectal 113 (8.1) 37 (9.4)
 Uterus 71 (4.5) 11 (1.9)
 >1 Recent diagnosis 30 (1.9) 8 (1.8)
 Other 388 (31.0) 141 (34.6)
Age at diagnosisa
 <50 532 (39.8) 117 (28.5)
 50–64 446 (34.2) 144 (37.2)
 ≥65 367 (26.0) 146 (34.3)
Time since diagnosisa
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All survivors, N= 1,345
N (%)
Diagnosis ≤4 yearsb, N=407
N (%)
 ≤5 503 (40.5)
 6–10 299 (21.4)
 >10 543 (38.1)
Treatment modalitiesa
 1 854 (63.1) 252 (61.2)
 2 329 (25.4) 97 (25.5)
 ≥3 162 (11.6) 58 (13.3)
Treatment recencya
 ≤12 months 147 (11.2) 112 (26.7)
 >12 months 1198 (88.8) 295 (73.3)
Clinical trial participation
 Yes 119 (9.1) 44 (10.5)
 No 1212 (90.9) 360 (89.5)
Health status
 Excellent/very good/good 988 (75.4) 296 (75.4)
 Fair/poor 355 (24.6) 111 (24.6)
FPL federal poverty level
a
Most recent cancer
bSurvivors diagnosed after recommendations for use of treatment summaries and written follow-up instructions were issued
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Table 3
Unadjusted associations of demographic, access, and health factors with reported receipt of treatment 
summaries, 2010 NHIS
All survivors Diagnosis≤4 yearsa
% (95 % CI) P % (95 % CI) P
Total 32.2 (29.2–35.4) 38.3 (33.0–43.9)
Age 0.0259 0.6131
 <50 33.2 (27.3–39.7) 36.7 (26.7–47.9)
 50–64 36.9(31.4–42.8) 43.0 (33.9–52.7)
 65–79 30.5 (25.5–35.9) 34.9 (26.4–44.4)
 ≥80 24.0(17.8–31.6) 35.1 (18.5–56.2)
Sex 0.0512 0.3347
 Male 35.6 (30.8–40.6) 41.1 (33.1–49.6)
 Female 29.9 (26.5–33.6) 35.6 (28.6–43.3)
Race/ethnicity <0.0001 0.0762
 Hispanic 49.5 (38.4–60.7) 47.1 (31.0–63.9)
 Non-Hispanic White 28.7 (25.3–32.4) 35.5 (29.2–42.3)
 Non-Hispanic Black 51.3 (43.0–59.5) 57.6 (43.2–70.9)
 Non-Hispanic Other 45.1 (27.8–63.6) 41.2 (16.8–70.9)
Education 0.3937 0.7900
 <High school 30.6 (26.2–35.3) 37.3 (29.3–46.0)
 ≥Some college 33.3 (29.2–37.7) 38.8(31.7–46.5)
Income (%FPL)b 0.4707 0.5765
 <250 % 34.4 (29.7–39.4) 39.4 (30.8–48.8)
 250–<400 % 29.3 (23.3–36.2) 33.2(23.1–45.1)
 ≥400 % 31.8(26.7–37.4) 40.6(31.6–50.2)
Insurance 0.2733 0.2905
 Any private/military 31.8(28.3–35.4) 38.4 (32.0–45.3)
 Public only 31.1 (25.5–37.2) 34.3 (24.1–46.1)
 Single service/none 42.3 (30.2–55.5) 52.3 (33.4–70.5)
Diagnosisc 0.0006 0.0592
 Breast 30.0 (24.3–36.5) 36.4 (25.7–48.7)
 Prostate 41.9(33.3–51.1) 41.1 (28.4–55.1)
 Cervix 35.2 (25.6–46.2) 51.3 (25.9–76.1)
 Melanoma 25.1 (17.4–34.6) 30.0 (16.7–47.9)
 Colorectal 48.5 (37.4–59.7) 65.7 (46.8–80.7)
 Uterus 25.1 (15.7–37.5) 59.7 (27.2–85.4)
 >1 12.9(4.5–32.1) 9.5(1.2–47.0)
 Other 29.0 (24.3–34.2) 31.9(23.5–41.7)
Age at diagnosisc 0.5804 0.5354
 <50 30.9 (26.5–35.6) 36.2(27.4–46.1)
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All survivors Diagnosis≤4 yearsa
% (95 % CI) P % (95 % CI) P
 50–64 34.4 (29.5–39.7) 42.1 (33.2–51.7)
 ≥65 31.3(25.8–37.4) 35.7(27.3–45.1)
Years since diagnosisb,c 0.0005
 ≤5 38.3 (33.3–43.5)
 6–10 32.6 (26.5–39.4)
 >10 25.3(21.2–29.8)
Treatment modalitiesc 0.7189 0.1227
 1 33.1 (29.4–37.0) 42.8 (36.0–49.9)
 2 31.6(26.1–37.6) 30.1 (21.0–41.2)
 ≥3 29.2(21.2–38.7) 33.6 (19.9–50.8)
Treatment recencyc 0.2334 0.6456
 ≤12 months 37.4 (29.0–46.7) 36.2 (26.2–47.5)
 >12 months 31.6(28.4–34.9) 39.1 (32.9–45.6)
Clinical trial participation 0.0421 0.3203
 Yes 43.0 (32.2–54.4) 45.9 (30.3–62.3)
 No 31.0(28.0–34.2) 37.4 (32.0–43.1)
Health status 0.0463 0.5700
 Excellent/very good/good 30.4 (27.0–34.0) 37.4(31.1–44.1)
 Fair/poor 37.8(31.6–44.3) 41.2(30.7–52.5)
FPL federal poverty level
aSurvivors diagnosed after recommendations for use of treatment summaries and written follow-up instructions were issued
b
May not sum to total due to rounding across multiple imputations
c
Most recent cancer
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m
m
en
da
tio
ns
e D
ef
in
ed
 a
s a
 m
am
m
og
ra
m
 w
ith
in
 2
 y
ea
rs
 a
m
on
g 
fe
m
al
e 
su
rv
iv
o
rs
 a
ge
d 
50
–7
4 
w
ith
 n
o 
br
ea
st 
ca
nc
er
 h
ist
or
y 
an
d 
>1
 y
ea
r p
os
t-d
ia
gn
os
is;
 F
O
BT
 w
ith
in
 1
 y
ea
r o
r f
le
x
ib
le
 si
gm
oi
do
sc
op
y 
w
ith
in
 5
 y
ea
rs
 o
r 
co
lo
no
sc
op
y 
w
ith
in
 1
0 
ye
ar
s a
m
on
g 
su
rv
iv
o
rs
 a
ge
d 
50
–7
5 
w
ith
 n
o 
co
lo
re
ct
al
 ca
nc
er
 h
ist
or
y 
an
d 
>1
 y
ea
r p
os
t-d
ia
gn
os
is;
 an
d 
Pa
p 
te
st 
w
ith
in
 th
e 
pr
io
r 3
 y
ea
rs
 a
m
on
g 
fe
m
al
e 
su
rv
iv
o
rs
 a
ge
d 
21
–6
5 
w
ith
 n
o 
ce
rv
ic
al
 c
an
ce
r h
ist
or
y,
 
n
o
 p
rio
r h
ys
te
re
ct
om
y,
 
an
d 
>1
 y
ea
r p
os
t-d
ia
gn
os
is.
 C
an
ce
r s
cr
ee
ni
ng
 te
sts
 ex
cl
ud
ed
 re
ce
nt
 te
sts
 d
on
e 
pr
io
r t
o 
di
ag
no
sis
f N
H
IS
 su
rv
ey
 it
em
 a
sk
s r
es
po
nd
en
ts 
ag
ed
 4
0+
 w
ho
 h
av
e 
N
OT
 h
ad
 a
 c
ol
on
os
co
py
 in
 th
e 
pa
st 
10
 y
ea
rs
, s
ig
m
oi
do
sc
op
y 
in
 th
e 
pa
st 
5 
ye
ar
s, 
CT
 co
lo
no
gr
ap
hy
 in
 th
e 
pa
st 
5 
ye
ar
s, 
or
 h
om
e b
lo
od
 st
oo
l t
es
t i
n 
th
e 
la
st 
ye
ar
,
 
w
he
th
er
 a
 d
oc
to
r o
r o
th
er
 h
ea
lth
 p
ro
fe
ss
io
na
l r
ec
om
m
en
de
d 
w
ith
in
 th
e 
pr
io
r y
ea
r t
ha
t t
he
y 
be
 te
ste
d 
to
 lo
ok
 fo
r p
ro
bl
em
s i
n 
th
ei
r c
ol
on
 o
r r
ec
tu
m
. P
ro
v
id
er
 re
co
m
m
en
da
tio
n 
qu
es
tio
ns
 fo
r P
ap
 a
nd
 
m
am
m
o
gr
ap
hy
 te
sti
ng
 w
er
e 
as
ke
d 
of
 re
sp
on
de
nt
s w
ho
 re
po
rte
d 
re
ce
iv
in
g 
re
ce
nt
 te
sts
 a
s w
el
l a
s t
ho
se
 w
ho
 d
id
 n
ot
g E
st
im
at
es
 b
as
ed
 o
n 
n
<
30
 o
r w
ith
 a
 re
la
tiv
e 
st
an
da
rd
 e
rro
r >
50
%
 ar
e i
nd
ic
at
ed
, b
u
t a
re
 n
ot
 s
ho
w
n
h E
st
im
at
es
 h
av
e 
a 
re
la
tiv
e 
st
an
da
rd
 e
rro
r o
f >
30
 a
nd
 ≤
50
%
 an
d 
do
 n
ot
 m
ee
t t
he
 st
an
da
rd
s o
f r
el
ia
bi
lit
y 
or
 p
re
ci
sio
n
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